Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review

BACKGROUND: Real-world comparisons of biologic treatment outcomes for ulcerative colitis (UC) or Crohn’s disease (CD) patients are limited. We sought to evaluate the real-world effectiveness of vedolizumab (VDZ) and anti-tumor necrosis factor alpha (anti-TNFα) in UC and CD patients in Germany. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Helwig, Ulf, Mross, Michael, Schubert, Stefan, Hartmann, Heinz, Brandes, Alina, Stein, Dara, Kempf, Christian, Knop, Jana, Campbell-Hill, Sarah, Ehehalt, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341567/
https://www.ncbi.nlm.nih.gov/pubmed/32640990
http://dx.doi.org/10.1186/s12876-020-01332-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341567/
https://www.ncbi.nlm.nih.gov/pubmed/32640990
http://dx.doi.org/10.1186/s12876-020-01332-w

Ejemplares similares